← boardnext 2027-06
ORKA
Oruka Therapeutics, Inc.distress 5/10 · elevated risk$91.45-1%today-4% from 52w high
Immunology / Inflammation 1
Lead: Plaque Psoriasis · target IL-23 · est. market ~$30B (approx, global)
Revenue
pre-revenue
Liquidity
$496M
Runway
5.5 yrs
Shares 1y
+61%
Price & events
+157.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
+10.1%
1W
+9.7%
1M
+35.0%
3M
+165.9%
6M
+529.0%
1Y
+354.2%
2Y
+377.1%
5Y
+240.6%
All
Overview
- Market Cap
- $5.52B
- Volume
- 60.66K
- 52 Week Range
- $13.05 – $95.17
- Total Shares
- 60.31M
- Float Shares
- 51.09M
- Short %
- 23.15%
- % Held by Insiders
- 1.23%
- % Held by Institutions
- 89.77%
- RVOL
- 0.04x
Pipeline stages · 1 programs
ORKA-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | ORKA-001 | Plaque Psoriasis | — | recruiting |
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | ORKA-002 | Plaque Psoriasis | — | recruiting |
| 2030-05 Estimated 50% readout ~2030-06-15 | Phase 2 | ORKA-001 | Plaque Psoriasis | — | recruiting |
| 2026-04 | Phase 2 | ORKA-001 Induction Dose, ORKA-001 Maintenance Dose | Plaque Psoriasis | 80 | active not recruiting |
| 2026-03-13 | Phase 1 | ORKA-001 | Healthy Volunteers | 24 | completed |
Catalyst news & presentations · 4
- 2027Guided 40%readoutPhase 2ORKA-002 · Phase 2 data readoutSEC 8-K
- second half of 2026Guided 55%readoutPhase 2ORKA-001 · Longer-term durability and safety follow-up from EVERLAST-A Phase 2a trial.SEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-05-29partnershipORKA-001 · Expanded IL-23 license to include inflammatory bowel disease; dosing restrictions: combination therapy delayed until June 1, 2028, monotherapy until June 1, 2030.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $145 (+58% upside) · 12 analysts
- 2026-07-13BTIGBuy
- 2026-07-01UBSBuy
- 2026-06-23HC Wainwright & Co.Buy
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-14BTIGBuy
- 2026-04-29HC Wainwright & Co.Buy
Competitors — IL-23
- none identified
Recent news
- 2026-07-20Saft to supply batteries for Dutch Orka-class submarines - bestmag.co.uk
- 2026-07-18Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-17ORKA Stock Climbs As Traders Track Tight Range - StocksToTrade
- 2026-07-17ORKA Stock Grinds Higher As Traders Track Tight Range - timothysykes.com
- 2026-07-17ORKA Stock Climbs As Traders Track Strong Cash Runway - StocksToTrade
- 2026-07-16Form 144 ORUKA THERAPEUTICS INC For: 15 July By Investing.com - Investing.com Australia
- 2026-07-16Form 4 Oruka Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
- 2026-07-15Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.